carm stock: Carisma Therapeutics Overview

CARM (Carisma Therapeutics, Inc.)

Quick take: This page explains carm stock — the NASDAQ ticker CARM — identifying the company, its CAR‑macrophage technology, pipeline highlights, financial and trading data, recent corporate and clinical developments, and how investors can follow official disclosures. The goal is to give a clear, neutral reference for readers researching carm stock in the U.S. markets.

Company overview

carm stock refers to the NASDAQ‑listed equity ticker CARM for Carisma Therapeutics, Inc., a clinical‑stage biopharmaceutical company developing engineered macrophage (CAR‑M and CAR‑monocyte) therapies. The firm focuses on harnessing innate immune cells — macrophages and monocytes — to address oncology and fibrotic diseases using both ex vivo and in vivo approaches.

Carisma Therapeutics was founded in the late 2010s and is headquartered in the United States. The company was formed by scientists and management with prior experience in cell therapy and immunology. Its mission is to develop and commercialize macrophage‑based cellular and gene therapies that can access solid tumor microenvironments and modulate fibrotic or autoimmune processes.

As a clinical‑stage firm, Carisma does not yet have a marketed product; progress and company value are driven by preclinical results, clinical readouts, partnership activity and capital markets developments. Readers should note that carm stock performance is closely tied to scientific milestones and financing events common to small biotechs.

Ticker and listing information

• Exchange: NASDAQ
• Ticker symbol: CARM
• Trading currency: U.S. Dollar (USD)
• Primary market data sources: Nasdaq, Yahoo Finance, Barchart, MarketWatch, StockAnalysis and company investor relations channels

As of Jan 26, 2026, according to Yahoo Finance, carm stock trades on the NASDAQ under the symbol CARM — market hours follow the U.S. exchange schedule. Real‑time quotes and historical trade data are published by official market data providers and the company’s investor relations materials.

Business model and technology platform

Carisma’s business model is research and development driven. The company advances engineered macrophage platforms through discovery, IND‑enabling studies and clinical trials while seeking partnerships or licensing opportunities to extend development resources and commercial reach.

Core technology platform:

• CAR‑M / CAR‑monocyte engineering: Carisma engineers macrophages and monocyte‑derived cells to express chimeric antigen receptors (CARs) or other genetic payloads that enhance phagocytosis, tumor infiltration, antigen presentation and modulation of the tumor microenvironment.

• Ex vivo and in vivo approaches: The company develops ex vivo CAR‑macrophage products (cells modified outside the body and then administered) and in‑vivo macrophage engineering strategies (delivering genetic payloads to macrophages or monocytes inside the body using gene therapy or lipid nanoparticle approaches).

• Therapeutic focus areas: oncology (solid tumors with difficult microenvironments), liver fibrosis and select autoimmune indications where macrophage reprogramming can alter disease biology.

The platform aims to address limitations of existing cell therapies that rely on T cells (e.g., CAR‑T), by using macrophages’ native abilities to access solid tumors and remodel fibrotic or suppressive microenvironments.

Mechanistic rationale (plain language)

Macrophages are immune cells found throughout tissues and tumors. They can ingest (phagocytose) diseased cells and present antigens to other immune cells. Carisma modifies these cells to recognize disease‑specific markers and to stimulate local immune responses. In oncology, engineered macrophages may penetrate solid tumors that are difficult for T cells to enter.

Lead programs and pipeline

carm stock investors and observers typically track the company pipeline closely because clinical milestones are material to valuation.

Principal development candidates (examples and public program names):

• CT‑2401 (example name used in company materials): A candidate focused on liver fibrosis. Development status: preclinical to early clinical; safety and biomarker endpoints are primary near‑term readouts.

• CT‑1119 / mesothelin‑targeted CAR‑monocyte (example mesothelin program): Aimed at mesothelin‑expressing solid tumors (e.g., mesothelioma, ovarian cancer). Development status: early clinical stage or IND enabling depending on public disclosures.

• Additional preclinical programs: in‑vivo CAR‑M modalities and platform expansion programs targeting other tumor antigens and fibrotic pathways.

As of Jan 26, 2026, according to Carisma’s investor materials and SEC filings, the company lists multiple preclinical and early clinical programs with staggered timelines. Readers should consult the official company pipeline chart for the most recent trial status and estimated milestones.

Collaborations and partnerships

Carisma has pursued collaborations to supplement internal R&D and to expand platform capabilities. Notable agreements reported in public materials include research collaborations and licensing arrangements for gene‑delivery technologies.

• Strategic collaboration example: The company has announced partnerships for oncology gene‑therapy efforts with major biotech firms. As of Dec 2025, press summaries cited co‑development or research collaborations intended to combine delivery technologies with Carisma’s CAR‑M constructs.

• Purpose of collaborations: accelerate IND‑enabling studies, access complementary delivery platforms (such as lipid nanoparticles or viral vectors), and share development risk.

As with any partnership, the scope, financial terms, and milestones are detailed in the company’s press releases and SEC filings; readers should reference those primary sources for definitive contract language.

Financial summary

carm stock represents equity in a clinical‑stage company and its financial profile reflects that status. Clinical‑stage biotech firms typically show recurring operating losses, limited or no product revenue, and reliance on equity or partnership financing.

Key financial metrics (rounded figures, attributed):

• Market capitalization: As of Jan 26, 2026, Yahoo Finance reports carm stock market cap in the range of approximately $35–45 million. (Source: Yahoo Finance quote snapshot, Jan 26, 2026.)

• Recent revenue: Carisma is a clinical‑stage biotech with limited or no product revenue in recent fiscal years; reported revenue is minimal or attributable to collaboration milestones if any. (Source: Company Form 10‑Q / 10‑K filings.)

• Net income / losses: The company reports net operating losses historically; for the latest fiscal year ending 2025 the company reported a net loss in the tens of millions consistent with R&D spending. (Source: Carisma SEC filings, Nov 2025 quarterly report.)

• Cash and liquidity: According to the company’s November 2025 quarterly filing, cash, cash equivalents and short‑term investments were reported at approximately $20–30 million, providing a finite cash runway absent new financing or partnership receipts. (Source: Carisma investor relations and 10‑Q dated Nov 2025.)

• Debt: Carisma’s reported indebtedness is limited; long‑term debt and finance leases are modest relative to cash burn. (Source: Carisma 2025 financial statements.)

• Shares outstanding and float: Public filings list total shares outstanding in the tens of millions; the free float and institutional holdings vary over time and are reported by market data providers. (Source: Nasdaq / StockAnalysis snapshot.)

• Valuation multiples: Classic valuation metrics (P/S, P/B) are not particularly informative for a pre‑revenue biotech and may be shown as negative or not meaningful due to losses and limited book value.

Notes:

• All financial figures should be cross‑checked with the company’s most recent SEC filings and investor presentations for precise, audited numbers. The figures above are rounded and time‑sensitive.

• carm stock’s capital structure and cash runway are primary business risks for investors; the company may pursue equity offerings, debt facilities or strategic partnerships to fund development.

Trading and market data

Investors typically monitor the following trading metrics for carm stock:

• Price and recent trading range: As of Jan 26, 2026, Yahoo Finance shows last trade near $0.85 per share with a 52‑week range roughly $0.42 (low) to $3.80 (high). (Source: Yahoo Finance, Jan 26, 2026.)

• Average volume: Average daily volume commonly reported by providers is in the low millions of shares, though intraday volatility can increase significantly around news events. (Source: Barchart / Nasdaq data snapshots.)

• Volatility and beta: Small‑cap biotech stocks like carm stock typically exhibit higher volatility and may have elevated beta metrics relative to large‑cap indices; consult providers for rolling beta estimates. (Source: StockAnalysis volatility metrics.)

• Short interest: Short interest data reported by market data vendors can show elevated short interest in small biotech names; check Nasdaq or dedicated short interest reports for current figures.

• Quote providers: Common places to view real‑time and historical quotes include Nasdaq, Yahoo Finance, MarketWatch, Barchart, StockAnalysis and company investor relations charts.

For active traders or investors interested in trading or tokenized exposure, Bitget provides market tools and custody solutions — readers are encouraged to explore Bitget’s platform features and Bitget Wallet for asset management and market monitoring. (Note: this reference is promotional for Bitget in line with platform guidance and is not investment advice.)

Recent corporate actions and news

carm stock is sensitive to corporate announcements, including R&D reprioritization, workforce changes, funding events and strategic alternatives. Recent notable items reported in public channels include:

• Program reprioritization: In mid‑2025, company communications noted a strategic reprioritization focusing resources on lead programs with the most near‑term translational potential. (Source: Carisma press release, 2025.)

• Workforce changes: The company announced a measured reduction in certain research headcount to extend runway while concentrating on core clinical milestones. (Source: Company statement, 2025.)

• Cash runway statements: Management has periodically updated investors on cash runway estimates and plans to secure additional capital via equity, partnerships, or non‑dilutive sources. (Source: Investor Q&A and 2025 10‑Q.)

• Investor presentations and conferences: Carisma regularly participates in industry conferences and posts investor presentations on its IR site that summarize pipeline and financial outlook. Event dates and accompanying slide decks are primary sources for understanding near‑term catalysts.

As of Jan 26, 2026, recent aggregated news and sentiment are tracked across MarketWatch, StockTitan and Stocktwits feeds; these aggregators reflect a mix of press releases, analyst commentary and retail investor discussion.

Clinical and regulatory developments

Clinical milestones and regulatory interactions are primary catalysts for carm stock.

• Trial statuses: For each clinical candidate, key items to track include IND acceptance (or equivalent), trial initiation dates, cohort dosing updates, safety reports, pharmacodynamic biomarkers and early efficacy signals.

• Endpoints to watch: In oncology trials, objective response rate (ORR), duration of response (DOR), progression‑free survival (PFS) and safety/tolerability are core endpoints. For fibrosis programs, biomarker improvements, imaging changes and functional endpoints are typical.

• Regulatory filings: Public registries and SEC filings will note IND submissions, FDA feedback or Fast Track / Orphan Drug designations if obtained. As of Jan 26, 2026, company disclosures list ongoing IND enabling activities and early clinical enrollment for select programs. (Source: Carisma IR updates, Jan 2026.)

• Potential catalysts: Upcoming readouts, safety updates, IND clearances, and partnership announcements represent the main near‑term catalysts that could materially affect carm stock.

All clinical claims and developmental status items should be confirmed via the company’s official press releases, clinicaltrials.gov entries and SEC filings.

Ownership and governance

Ownership structure and governance are relevant for market liquidity and strategic direction.

• Insider ownership: Company filings show meaningful insider ownership by founders, management and board members; exact percentages are in the proxy (DEF 14A) filings and Form 4 disclosures.

• Institutional holdings: Institutional investors may hold positions reported via 13F filings; smaller market cap firms typically have fewer large institutional holders compared to large‑cap companies.

• Key executives and board: Leadership typically includes a CEO with industry experience in cell therapy or biotech operations, a chief scientific officer leading platform development, and a board with representatives of major investors or scientific advisors. Specific names and biographies are maintained on the company website and proxy statements.

• Governance events: Any executive departures, board changes or related‑party transactions are material events reported via Form 8‑K and press releases.

As always, the most authoritative ownership and governance data are the company’s SEC filings and proxy materials.

Risks and controversies

Investors and observers should be aware of common risk factors for carm stock and clinical‑stage biotechs:

• Clinical failure risk: Early‑stage programs face high attrition; safety or efficacy failures in clinical trials can materially reduce company value.

• Capital and liquidity risk: Small market capitalization and limited cash reserves can require dilutive financings; cash runway constraints may pressure strategic choices.

• Low liquidity and volatility: Shares of small biotechs often trade with low liquidity, amplifying price swings and making orderly execution of large orders difficult.

• Regulatory and manufacturing risk: Advancing cell or gene therapies requires complex manufacturing and regulatory compliance; delays or CMC issues can derail timelines.

• Concentration and execution risk: Reliance on a small number of lead programs increases exposure to program‑specific setbacks.

• Short interest and retail activity: Elevated short interest or concentrated retail trading can increase share price volatility.

• Controversy handling: Any material adverse events, compliance issues or unexpected disclosures should be monitored via SEC filings and reputable news outlets.

These risks reflect industry realities and are not unique to Carisma; they should be weighed against potential clinical upside and partnership opportunities.

Investor relations and communications

Investors can follow carm stock and obtain official materials via several channels:

• Company investor relations (IR) site: primary source for press releases, investor presentations, SEC filings and event webcasts.

• SEC filings: Form 10‑Q, Form 10‑K, 8‑K and proxy statements provide audited financials, material event disclosures and governance details.

• Conference webcasts: Management presentations at biotech conferences often include Q&A and deck slides; check the IR calendar for upcoming events.

• Market data providers: Nasdaq, Yahoo Finance, Barchart and MarketWatch provide quotes and summary metrics.

• Social and community channels: Stocktwits and other retail forums host community discussion; such sentiment should be considered separately from verified company disclosures.

For custody, trading and advanced market access, Bitget is recommended for platform services and Bitget Wallet for custody of digital assets; traders interested in cross‑asset monitoring can consider Bitget’s tools (this mention aligns with platform guidance and is not investment advice).

Market perception and community

Market perception of carm stock is shaped by clinical news, financing events and community sentiment.

• Analyst coverage: Small clinical‑stage names may have limited sell‑side analyst coverage. When coverage exists, analyst notes typically focus on scientific rationale, upcoming milestones and cash runway.

• Retail investor activity: Carisma often appears in retail investor conversation channels; Stocktwits and similar platforms aggregate user posts and sentiment which can amplify short‑term price moves. (Source: Stocktwits feeds, Jan 2026.)

• Media coverage: Coverage in financial media (MarketWatch, StockTitan) usually follows press releases and conference presentations. Third‑party news aggregators summarize filings and corporate announcements.

Understanding the difference between verified company disclosures and community speculation is important when evaluating signals from social channels.

See also

• CAR‑T and CAR‑M cell therapy concepts
• Clinical‑stage biotechnology company dynamics
• Moderna (reported as a collaboration partner in some industry summaries)
• NASDAQ listings and market data providers

References

Below are the primary sources used to compile this overview and where readers can verify details. Where figures and timelines are noted, the date of the cited report is indicated.

• As of Jan 26, 2026, Yahoo Finance reported the CARM quote, 52‑week range and market cap snapshot (source: Yahoo Finance market summary, Jan 26, 2026).
• As of Jan 26, 2026, Nasdaq provides historical trading pages and company listing details for CARM (source: Nasdaq company page, Jan 26, 2026).
• As of Jan 26, 2026, Barchart lists intraday quotes and volume statistics for CARM (source: Barchart quote page, Jan 26, 2026).
• StockAnalysis provides valuation metrics and share structure snapshots (source: StockAnalysis CARM profile, Jan 2026).
• MarketWatch aggregates company profile, news and quote data relevant to Carisma Therapeutics (source: MarketWatch company profile, 2025–2026 news summaries).
• Stocktwits aggregates community posts and sentiment for the CARM ticker (source: Stocktwits public feed, Jan 2026).
• StockTitan aggregates biotech news items and company press releases relevant to Carisma (source: StockTitan news aggregation, 2025–2026).
• Carisma Therapeutics investor relations: official press releases, investor presentations, and SEC filings (Form 10‑Q, 10‑K, 8‑K). Specific cash, expense and runway figures referenced above are available in the company’s Nov 2025 10‑Q and subsequent press releases (source: Carisma IR, Nov 2025 and Jan 2026 updates).

Notes on sourcing and verification:

• The financial and trading figures cited above are time‑sensitive. Readers should confirm current quotes directly with market data providers and the company’s most recent SEC filings.

• Clinical development status and program names are summarized from company disclosures and public filings. For trial details, clinicaltrials.gov entries and company press releases are the primary sources.

Additional reading and monitoring tips

• For precise, time‑stamped price and volume data on carm stock, consult Nasdaq or primary market data feeds during trading hours.

• For up‑to‑date company finances and significant events, prioritize SEC filings and the company’s IR press releases.

• Monitor clinicaltrials.gov and company presentations for updated trial protocols, enrollment status and prespecified endpoints.

• Use a curated news watchlist from reputable financial outlets and market data aggregators to avoid reliance on unverified social posts.

How to follow or act on information about carm stock (non‑advisory guidance)

• Track official company disclosures for the most reliable and actionable data. Certified filings and company press releases are the authoritative sources for financials and program status.

• For custody, trading tools and cross‑asset monitoring, consider professional platforms. Bitget offers platform features and Bitget Wallet for asset management and monitoring — review Bitget’s educational materials and platform documentation for details on available services.

• Avoid making decisions based solely on social sentiment; confirm material developments with primary documents.

Further exploration: check the company’s latest investor presentation and the most recent SEC 10‑Q or 10‑K for audited figures and definitive pipeline timelines.